Zhifei Biological's controlling subsidiary, Chengan Bio, has received approval for its Degludec Insulin Injection. This marks a significant step in expanding its diabetes treatment portfolio. The approval is based on the product's quality and efficacy, aiming to provide patients with advanced therapeutic options.
The approval of Degludec Insulin Injection by Zhifei Biological's subsidiary, Chengan Bio, strengthens its position in the diabetes market. This new product offers an advanced treatment option, potentially capturing market share from existing therapies and enhancing the company's revenue streams in a growing therapeutic area.
Chengan Bio's Degludec Insulin Injection receives approval.
Expands Zhifei Biological's diabetes treatment portfolio.
Aims to provide advanced therapeutic options for patients.
This development is significant for the Chinese pharmaceutical market, particularly in the diabetes segment. The approval of a new insulin formulation by a domestic company like Zhifei Biological indicates growing self-sufficiency and innovation in China's biopharmaceutical sector, potentially impacting both domestic and international competitors.
Expands Zhifei Biological's diabetes treatment portfolio.
Aims to provide advanced therapeutic options for patients.
Sign in to save notes on signals.
Sign In